An interventional study of Postpartum Cardio-obstetric Rehabilitation Program in Gestational Hypertension and Preeclampsia (PE), sponsored by Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal. Not yet recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-14.
Sponsored by Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Pre-Eclampsia with a site in Canada — 4 open to participants now, 5 under way, 1 of them phase 3. Pre-Eclampsia · Canada.
Among the 31 studies in Pre-Eclampsia with a site in Canada, this one is the 17th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2025, is one of 11 with no phase, and was the 31st registered.
918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
Browse Pre-Eclampsia studies →4 of the 31 studies in Pre-Eclampsia with a site in Canada are open now. Recruiting first, the newest first:
University of Calgary · Sites in Canada, Belgium, Denmark and 4 more countries
Ages 18+ · Women only
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+ · Women only
CHU de Quebec-Universite Laval · Sites in Canada
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 110 across 482 interventional studies indexed under Pre-Eclampsia.
Median enrollment 73 across the 19 interventional studies, 370 across the 12 observational. Of the 21 that completed or were terminated, 2 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 31 has an industry lead sponsor. The 10 most frequent:
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal is the lead sponsor of 34 studies on the registry; 16 are open to participants now.
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal has 1 study filed under Pre-Eclampsia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 31 studies in Pre-Eclampsia with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Some women who develop high blood pressure during pregnancy, such as gestational hypertension or preeclampsia, may continue to have slightly or moderately high blood pressure after giving birth. This can increase their risk of heart disease later in life. Managing blood pressure and adopting a healthy lifestyle after pregnancy could help lower this risk.
Right now, the investigators don't know much about how postpartum rehabilitation programs focused on heart and pregnancy-related health could help women with these conditions. However, a feasibility study suggests that exercise programs might help reduce blood pressure and encourage healthier lifestyles in these women.
In this study, the investigators are testing an 8-week exercise program to see how it affects blood pressure, fitness, and blood vessel health. The investigators will compare the results with a group of women who receive usual healthcare, which includes verbal advice on healthy living but no supervised exercise sessions.
This type of program, called cardio-obstetric rehabilitation, combines exercises for heart health with specialized care for women's health.
Women with severe hypertensive disorders during pregnancy, such as preeclampsia (PE), have a higher risk of heart disease and stroke within five to 10 years of their pregnancy. Because their blood pressure (BP) drops in the postpartum period in comparison to the values they had during pregnancy, the hypertensive disorder can be considered resolved. However, recent studies have shown that their postpartum BP may be higher than before pregnancy. Hypertensive pregnancy has been associated with endothelial and microvascular dysfunction and capillary rarefaction, which could be the key mechanism leading to elevated BP in the postpartum period. Studies have shown that physical exercise promotes BP reduction, stimulates angiogenesis and improves microcirculation in healthy subjects, but also in patients with cardiovascular and metabolic diseases. Therefore, interventions to better monitor BP combined with a healthy lifestyle could help reduce the risk of heart disease in later years. The effects of postpartum cardio-obstetric rehabilitation in women with gestational hypertension (GH) or PE are still unknown. It is of interest to determine whether a postpartum cardio-obstetric rehabilitation program could reduce BP, identifying the possible mechanisms, and stimulate the adoption of a healthy lifestyle with potential long-term health benefits for women.
The main objective of this study is to describe the effects of an 8-week rehabilitation program combining aerobic exercise with obstetric rehabilitation starting between 3 to 6 months postpartum on BP changes, vascular structure and physical activity levels, which could lead to long term health benefits compared to usual care in women with previous GH and PE. The 8-week rehabilitation program will include cardiac (aerobic exercise) and obstetric (pelvic floor training, core and balance) exercises, as well as online education courses about healthy lifestyle. The outcomes will be compared with participants submitted to the usual care in the postpartum. At the end of the study participation period, participants of the control group will be offered to participate in the intervention program (crossing study).
The following outcomes will be evaluated, before and immediately after the intervention: ambulatory and 24-hour BP, arterial stiffness, pulse wave velocity, static retinal vessels analysis, body composition (including body mass index), physical capacity (6-minute walk test), physical activity level (number of daily steps), lipid and glucose profiles, quality of life (SF-36), as well as plasmatic angiogenic biomarkers and the angiogenic function of circulating endothelial cells. Moreover, 6-months post-intervention, participants will be submitted again only to physical evaluation to assess the long-term effects of the intervention program.
Cardio-obstetric rehabilitation is a new field, lacking the description and evaluation of effective programs. The investigators expect that the results obtained from this study will contribute to the design of a patient-oriented rehabilitation program. Our findings will provide the first evidence to support postpartum rehabilitation services in clinics which in turn could lead to long term health benefits to women.
918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
This study's planned enrollment of 40 is below the median of 110 across 482 interventional studies indexed under Pre-Eclampsia.
Browse Pre-Eclampsia studies →Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal is the lead sponsor of 34 studies on the registry; 16 are open to participants now.
Compared within Pre-Eclampsia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pregnancy-Induced. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The rehabilitation Group will be submitted to an 8-week exercise and education program with a hybrid format, delivered by a professional physiotherapist at the Centre Jean-Jacques Gauthier (CJJG). Briefly, one in-person session (60 minutes of aerobic exercise and full-body strength exercise), one online session (30-35 minutes - focus on pelvic floor muscle training, core/abdominals, balance, and stretching exercises), and one pre-recorded video (30 minutes - exercise instructions) will be delivered per week. Participants will use Fitbit Charge-6 to progressively reach daily 10,000 steps throughout the intervention period. Four online educational workshops on healthy lifestyle will be delivered.
Other: Postpartum Cardio-obstetric Rehabilitation Program
Control group participants will received the usual care, together with information about the guidelines for physical activity practice, nutritional and risk factor monitoring instructions, pelvic floor exercise instructions, and recommendations to progressively reach daily 10,000 steps according to guidelines . Participants will also receive a Fitbit device.
The intervention consists of an 8-week exercise and education program with a hybrid format (in person, virtual and pre-recorded sessions). The aerobic exercise intensity will progressively increase from 50 to 85% of Targeted Heart Rate Range (THRR), calculated for middle-aged women using the maximal heart rate (HR) estimated as 206 - (0.88 x age) . First and second weeks training will target an intensity of 50-65% THRR, third and fourth weeks will target 65 to 75% of THRR, fifth to seventh weeks will target 75 to 80%, and eighth week will target 85%. Participants will use Fitbit Charge-6 to monitor THRR during exercise sessions. Pelvic floor, body alignment/core stability, balance, and low back pain prevention exercises will be added to each in-person session and repeated during the online session. Participants from the intervention group will receive recommendations to progressively reach daily 10,000 steps throughout the intervention period.
Office Blood Pressure
Resting office BP will be measured with the patient in the sitting position after 5 minutes at rest using a validated automated sphygmomanometer according to established practice guidelines . Three readings will be taken at intervals of 2 minutes.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
24-hour Ambulatory Blood Pressure
24-hour Ambulatory Blood Pressure using OSCAR 2 equipment.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Static Retinal Vascular Analysis
Retinal microvasculature imaging will be taken using Static Vessel Analyzer (SVA-T, Imedos) through non-invasive procedures described by Hanssen's team .
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Peripheral artery stiffness - PWV
Peripheral artery stiffness will be measured using SphygmoCor XCEL system through pulse wave velocity (PWV) as described by Daskalopoulou's team.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Peripheral artery stiffness - PWA
The Sphygmocor XCEL system will be used to assess arterial stiffness through Pulse Wave Analysis (PWA), according to the instruction guidelines.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Physical capacity (6MWT)
Six-minute walk test will be performed following the protocol described by the American Thoracic Society.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Physical activity levels
All participants will receive a wrist worn heart rate and accelerometer monitor (Fitbit Charge 6). This device will be used to monitor physical activity levels (total steps per week) and targeted heart rates during exercise training.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Body composition
Body composition will be measure using a bioimpedance scale InBody 570.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Timed Up and Go (TUG)
TUG test: The objective of TUG test is to assess mobility, balance and fall-risk. It consists of the participant stand-up from a chair, walk 3 meters, turn, walk back and sit down again. Interpretation: test performed ≤10 seconds indicates normal mobility.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Handgrip strength
The maximal handgrip strength will be performed using a manual Jamar Hydraulic Hand Dynamometer.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Glucose
Blood draw by venipuncture will be collected to measure glucose at the Biochemistry laboratory of the MUHC.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Angiogenic and proliferative function of peripheral blood ECFCs
Endothelial cell function will be assessed by the procedures described by Bertagnolli's team . ECFCs = Endothelial colony forming cell
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Plasmatic levels of angiogenic factors - VEGF
Serum concentration of angiogenic factors by ELISA following manufacturer instructions - Vascular endothelial growth factor (VEGF)
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Heart rate variability
R-R intervals will be recorded using a Vantage V2 Polar heart rate monitor at a sampling rate of 1,000 Hz. HRV will be recorded during deep breathing maneuver (continuous cycles) for 4 min in a supine position. HRV will be analyzed using Kubios HRV software following guidelines from the Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Circulating Endothelial Cells (cEC) Function
cEC tube formation capacity on matrigel, proliferation, and migration capacities.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Total cholesterol
Blood draw by venipuncture will be collected to measure total cholesterol at the Biochemistry laboratory of the MUHC.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Insuline
Blood draw by venipuncture will be collected to measure total cholesterol at the Biochemistry laboratory of the MUHC.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Glycated hemoglobin (HbA1c)
Blood draw by venipuncture will be collected to measure HbA1c at the Biochemistry laboratory of the MUHC.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
LDL cholesterol
Blood draw by venipuncture will be collected to measure LDL-cholesterol at the Biochemistry laboratory of the MUHC.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
HDL cholesterol
Blood draw by venipuncture will be collected to measure HDL cholesterol at the Biochemistry laboratory of the MUHC.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Triglycerides
Blood draw by venipuncture will be collected to measure triglycerides at the Biochemistry laboratory of the MUHC.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Brain Natriuretic Peptide (NT-PRO-BNP)
Blood draw by venipuncture will be collected to measure NT-PRO-BNP at the Biochemistry laboratory of the MUHC.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
C-reactive protein (CRP)
Blood draw by venipuncture will be collected to measure C-reactive protein (CRP) at the Biochemistry laboratory of the MUHC.
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Plasmatic levels of angiogenic factors - NO
Serum concentration of angiogenic factors by ELISA following manufacturer instructions - Nitric Oxide (NO).
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
SF-36 Quality of Life Questionnaire (SF-36).
Health status will be evaluated based on: SF-36 Quality of Life Questionnaire (SF-36).
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Patient Health Questionnaire-9 (PHQ-9)
Health status will be evaluated based on: Patient Health Questionnaire-9 (PHQ-9) for depression symptoms
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Edinburgh Postnatal Depression Scale (EPDS).
Health status will be evaluated based on: Edinburgh Postnatal Depression Scale (EPDS).
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Pittsburgh Sleep Quality Index (PSQI).
Health status will be evaluated based on: Pittsburgh Sleep Quality Index (PSQI).
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Pregnancy Physical Activity Questionnaire (PPAQ).
Physical activity will be also evaluated based on Pregnancy Physical Activity Questionnaire (PPAQ).
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Duke Activity Status Index (DASI)
Physical activity will be also evaluated based on Duke Activity Status Index (DASI)
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
International Physical Activity Questionnaire (IPAQ).
Physical activity will be also evaluated based on International Physical Activity Questionnaire (IPAQ).
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Pelvic Floor Distress Inventory (PFDI-20)
Pelvic health will be evaluated by Pelvic Floor Distress Inventory (PFDI-20)
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Urogenital Distress Inventory (UDI)
Pelvic health will be evaluated by Urogenital Distress Inventory (UDI).
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Pelvic Floor Impact Questionnaire (PFIQ-7).
Pelvic health will be evaluated by Pelvic Floor Impact Questionnaire (PFIQ-7).
Time frame: Baseline, immediately post-intervention, and 6-month post-intervention
Plan to share: No
Start is estimated for Jun 2025; primary completion for Aug 2026, 14 months later.
Of 172 non-industry interventional studies with no phase under Pre-Eclampsia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 14 months is below that.
Counting every sponsor, half of 177 studies reached it within 24 months; a quarter within 10 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal